Advion BioServices: Prescription for Scientific Excellence Advion BioServices, Inc. premiered this video at the FIP Pharmaceutical Sciences World Congress (PSWC) 2010 in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition on Sunday, November 14 in New Orleans. In this video, several Advion employees discuss their "prescription for scientific excellence". They are introduced by David B. Patteson, president and CEO; Jack Henion, co-founder, CSO and chairman; and Tom Kurz, co-founder and president, BioServices and corporate development. Advion is a contract research organization (CRO) dedicated to scientific excellence. With a deep understanding of LC/MS/MS, biomarkers, and immunoassay technologies, Advion is the bio***ytical laboratory of choice for pharmaceutical and biotechnology companies demanding scientific excellence, an exemplary regulatory track record, uncompromised quality, delivery to timelines, and open, honest communications. More about the company can be found at .
Making the Right Connections for Small Businesses Apply now for Delaware's 2012 State Trade & Export Promotion Grant Program! laware.gov The State of Delaware International Trade Office, with support from the US Small Business Administration and assitance from the US Commercial Service, brought delegations of small businesses to China and Brazil in 2012. Are you interested in joining our next trip? Visit laware.gov to apply and www.sba.gov to learn more about SBA resources. Thanks to Ray Yin, President and Chief Technology Officer at ANP Technologies, for this interview:
Immunogenicity Prediction and Mitigation
OX40 INHIBITION OF TREG SUPPRESSION - IMMUNOTHERAPY OF CANCER - 2nd European Congress of Immunology The 2nd European Congress of Immunology - Immunity for Life, Immunology for Health -- IMMUNOTHERAPY OF CANCER - OX40 INHIBITION OF TREG SUPPRESSION - Speaker: MP Colombo - ICC Berlin - 16.09.2009
Antigens.... Antigens The terms immunogen and antigen are often used synonymously. However, these terms imply two closely related entities. The first describes a molecule that provokes an immune response(immunogenicity) and hence is called an immunogen. The other describes a molecule which reacts with the antibody produced, or with the activated cellular constituents of cell mediated immunity(antigenicity), and is referred to as an antigen. In contrast to this is the hapten. Haptens are small well defined chemical groups such as dinitrophenol (DNP) which are not immunogenic on their own but will react with preformed antibodies. To make a hapten immunogenic, it must be linked to a carrier molecule which is itself immunogenic. Antigens are recognized not only by antibodies, but also by antigen specific T cell receptors. In contrast to immunoglobulins, which usually recognize intact antigens, T cell surface receptors recognize processed antigens on the surface of antigen presenting cells.
Immunogenicity of Pandemic H1N1 Vaccine in HIV-Infected Patients Curtis Cooper is a Medical Doctor (MD), a Fellow of the Royal College of Physicians of Canada (FRCPC), and holds a Master of Science (MSc) in Epidemiology. In addition, he is an Associate Professor of Medicine, in the Division of Infectious Diseases, at the University of Ottawa at the Ottawa Hospital. He presented his research on the immunogenicity of adjuvanted pandemic H1N1 vaccine in HIV-infected patients as part of his work with PCIRN at our symposium in April 2011.
Biological modeling for the life science industry: A blackboard introduction This video shows a short, blackboard introduction to the computer modeling and simulation services offered by Digital Biology Partners, which was founded with the goal of helping life science companies to develop more effective therapies and diagnostics through a mechanistic approach to biology.
euronews innovation - HIV vaccine on trial A team of French scientists has started clinical trials on humans for a potential HIV/AIDS vaccine. Chief Scientific Officer at Grenoble-based PX'Therapeutics Nicholas Mouz said: "We're developping a vaccine against HIV, using a protein of the HIV virus called GP41. "Why the GP41 protein? Because it's a key protein in the mechanism of entry of the virus into the cells. "And it's a protein which allows the generation of neutralising antibodies, which is the main objective of the vaccine." Protein GP41 - remember that name, because that protein could help European researchers overcome one of the world's most pernicious diseases: HIV/AIDS. The team at PX'Therapeutics believes GP41's low level of genetic variability means it could allow them to develop a truly ground-breaking vaccine. Nicholas Mouz explained: "The idea is to look for an immune response of neutralising antibodies in the mucus. Why in mucus? Because nearly 90% of AIDS cases are due to ***ual relations." These French researchers are part of a European project that includes clinical trials of their HIV vaccine. The team is following closely as 50 British volunteers take part in the first round of tests. PX'Therapeutics' pharmaceutical director is Lucile Marron Brignone. She said: "After each administration of the product we check if there are any side effects. "The other objective is to have information about the immunogenicity of the product, that's to say whether or not it generates an immune ...
Oxford Global's Proteins Congress, London Testimonials from Oxford Global's Annual Proteins Congress and co-located Vaccines Congress, held on the 2nd and 3rd of April 2012
QUALITY ASSISTANCE HD High Corporate video (Quality Assistance) Quality Assistance (QA) is a leading European Contract Research Organisation (CRO) providing pharmaceutical and biopharmaceutical companies with the ***ytical services needed to support the development and marketing of new medicinal drugs. QA holds a unique position on the market thanks to its six laboratories - Mass Spectrometry, Physico-chemistry, Bio***ysis, Cell Culture, Molecular Biology and Microbiology - on one site and its expertise at the forefront of ***ytical sciences. Quality Assistance services are used to prove the QUALITY, SAFETY and EFFICACY of innovative drugs. They are presented by product category (NCEs, Abs, etc.) and type of study (eg: development and validation of (bio)***ytical methods, stability, bio***ysis for PK/TK and immunogenicity).
REGULATORY T CELLS IN CANCER AND THEIR SUPPRESSION AS A STRATEGY TO ENHANCE THE EFFICACY - CANCER The 2nd European Congress of Immunology - Immunity for Life, Immunology for Health -- IMMUNOTHERAPY OF CANCER - REGULATORY T CELLS IN CANCER AND THEIR SUPPRESSION AS A STRATEGY TO ENHANCE THE EFFICACY OF IMMUNOTHERAPEUTICS AND VACCINES - Speaker: K. Mills, Dublin - ICC Berlin - 16.09.2009
R&D: Immunome-Derived vaccines- Dr Timothy Messitt EpiVax World Vaccine Congress Vaccine design: what's next? Last April Dr Timothy Messitt from EpiVax delivered a presentation about the next wave of vaccine design on immune-derived vaccines at the World Vaccine Congress Washington. See below the key highlights of his presentation: Immunome-derived are T cell epitope driven vaccines that were developed in order to improve safety (limited potential for autoimmunity) and immunogenicity. Would like to take this into biodefense portfolio. The focus is on T cell epitopes being able to predict T cell epitopes (Class 1 and 2 MHC binding) using EpiMatrix. The process goes through the following phases: 1. T cell epitope identification: ■CLUSTIMERS (identifies epitope clusters); potent epitops are promiscuous ■CONSERVATRIX finds conserved 9mers to be able to protect against as many strains possible ■Removal of cross-reactive epitopes 2. Expressing epitopes, usually by DNA plasmids followed with peptide boost; optimized whole proteins or VLPs with iso-optimized proteins 3. In vivo evaluation by HLA binding assays Current vaccines: Burk/Tuly/MP, HIV/TB, Smallpox (VennVax) and others The company is focusing on an accelerated vaccine approach focusing on biodefense and is planning to integrate all technologies in a web-based toolkit, iVax (currently beta testing it). Dr Timothy Messitt, Manager, Business Development, EpiVax Visit our Website: Read our blog: Follow us on Twitter: @vaccinenation Join our Linkedin group: www ...
ADVERSE IMMUNE REACTIONS_Q&A (part 1/2) Immunogenicity: Assessing the clinical relevance and risk minimization of antibodies to biopharmaceuticals Presenter: Daniel Kramer - EFPIA topic writer Moderator: Maria Teresa De Magistris
Immunogenicity Assessment and Clinical Relevance
ADVERSE IMMUNE REACTIONS (Part 2/3) Immunogenicity: Assessing the clinical relevance and risk minimization of antibodies to biopharmaceuticals Presenter: Daniel Kramer - EFPIA topic writer Moderator: Maria Teresa De Magistris
How to Pronounce Immunogenic Learn how to say Immunogenic correctly with EmmaSaying's "how do you pronounce" free tutorials. Definition of immunogenic (oxford dictionary): adjective relating to or denoting substances able to produce an immune response: immunogenic vaccines Derivatives immunogenicity noun Take a look at my comparison tutorials here Subscribe to my channel here :
ADVERSE IMMUNE REACTIONS (Part 1/3) Immunogenicity: Assessing the clinical relevance and risk minimization of antibodies to biopharmaceuticals Presenter: Daniel Kramer - EFPIA topic writer Moderator: Maria Teresa De Magistris
Cord blood stem cells immunogenicity : prof.Dr.Dominique Charron Cord blood stem cells immunogenicity : prof.Dr.Dominique Charron 14th Egyptian -- French Seminar of immunology & Molecular
LOW-DOSE CYCLOPHOSPHAMIDE TREATMENT AUGMENTS ANTITUMOR IMMUNE RESPONSES - IMMUNOTHERAPY OF CANCER The 2nd European Congress of Immunology - Immunity for Life, Immunology for Health -- IMMUNOTHERAPY OF CANCER - LOW-DOSE CYCLOPHOSPHAMIDE TREATMENT AUGMENTS ANTITUMOR IMMUNE RESPONSES AND TUMOR IMMUNOGENICITY IN RET TRANSGENIC MOUSE MELANOMA MODEL - Speaker: A. Sevko - ICC Berlin - 16.09.2009
Vector design for vaccine and gene therapy applications Extensive research to improve plasmid delivery has resulted in advanced methods such as electroporation that dramatically improve gene transfer compared with *** DNA delivery. Plasmid-directed gene expression is now near the efficacy barrier that to date has prevented DNA medicine commercialization for human applications. However, most DNA vaccines and non-viral gene therapeutics currently in development utilize suboptimal vector backbones. In this webinar I will discuss DNA vaccine vector and synthetic gene insert design strategies that may be applied to create regulatory agency compliant non viral plasmid vectors with improved transgene expression and immunogenicity. Dr. Williams is the Chief Scientific Officer and Vice President, Research and Development, at Nature Technology Corporation (NTC). Dr. Williams has 17 years biotech industry experience directing microbial fermentation, cell line, & vector design programs for protein & DNA-based vaccine or therapeutic product applications. He oversaw development of NTC's minimal antibiotic-free plasmid vector/manufacturing platform for DNA vaccination and gene therapy applications. ### In response to ConorC96's question
Professor Karl Griswold: Therapeutic Protein Research Dartmouth Professor of Engineering Karl Griswold, Professor of Computer Science Chris Bailey-Kellogg, and grad student Andrew Scott Parker are developing an integrated suite of general methods combining computation and experiment in order to produce immunotolerant variants of therapeutic proteins, in which immunogenicity is reduced while therapeutic activity is maintained. Thank you to Neukom Institute for its use:
Anti-PEG Antibody Pair ( ) - Polyethylene Glycol (PEG) is a long chain polymer that has been approved by the Food and Drug Administration for human intravenous, oral and dermal applications. Covalent attachment of PEG (PEGylation) to proteins can reduce their immunogenicity, minimize proteolytic cleavage and increase their serum half-life. PEG has also been attached to small molecules and liposomes for more selective delivery. PEG-modification of superparamagnetic iron oxide and quantum dots can improve their biocompatibility and reduce non-specific uptake. This video shows the procedure of sandwich ELISA assay for anti-PEG antibody pair. More videos at Abnova http
New Childhood TB Vaccine Is Better Off Alone An informal conversation with Dr. Martin Ota at the Bacterial Diseases Programme, Medical Research Council Laboratories in Banjul, Gambia. Thisvideo relates to a paper that appeared in the June 22, 2011, issue of Science Translational Medicine, published by AAAS. The paper, by Dr. Martin Ota of Bacterial Diseases Programme, Medical Research Council Laboratories in Banjul, Gambia and colleagues, was titled, "Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants."
Production Of Therapeutic Glycoproteins : Competitor and Patent Landscape Report About the Report: The majority of clinically approved protein drugs bear some form of post-translational modification, most commonly glycosylation. Glycosylation is the attachment of a carbohydrate group to a protein, catalyzed by enzymes called glycosyl transferases. It is either N-linked, in which a carbohydrate is attached to the side chain of a specific asparagine, or O-linked, in which it is attached to the hydroxyl oxygen of a serine or threonine, the former being most prominent. While N-linked glycosylation occurs largely in the endoplasmic reticulum (ER) of mammalian cells, O-linked glycosylation initiates in either the ER or Golgi apparatus. Glycosylation is important because it can influence the therapeutic efficacy, immunogenicity, solubility, and in-vivo half life of the glycoprotein. A major obstacle in the pharmaceutical application of glycoproteins is the inherent heterogeneity of their glycan structures. Mammalian cell culture systems, especially Chinese hamster ovary (CHO) cells, are the preferred method for the production of therapeutic glycoproteins. Other systems such as E.coli, filamentous fungi, yeast, insects, plants and transgenic animals are also being engineered to produce proteins with optimal glycosylation pattern. Optimizing production methods to obtain a glycoform profile as similar to that in humans is the current goal in glycoengineering research. Some of the bestsellers among therapeutic proteins will soon lose patent protection. Therefore ...
snow storm 2010 Rapp 1.mp4
Partnering & corporate strategy: Eliciting mucosal and systemic immunity- Dr Jakub K. Simon Subscribe: NanoBio Corporation announced earlier this week the initiation of a second tolerability and immunogenicity study designed to test and further optimize its novel nanoemulsion-based intranasal vaccine adjuvant. Read full press release from NanoBio. In 2009, NanoBio tested its nanoemulsion adjuvant in combination with the commercial influenza vaccine Fluzone®, in a first-in-man Phase 1a study of 199 healthy adults. The intranasal nanoemulsion vaccine was well tolerated in the study and elicited both mucosal and systemic immune responses after a single administration by dropper. In the current Phase 1b study, the nanoemulsion adjuvant will again be combined with Fluzone®, and will be administered by both a sprayer device and a dropper to study the potential impact on immune response. The sprayer device will be tested using two different volumes of the vaccine. Mucosal, systemic humoral and cellular-mediated immune responses will be examined in all subjects. Ali I. Fattom, Ph.D., Senior Vice President Vaccine Research and Development, commented, "We were pleased with the safety outcome and adjuvant effect of our novel NanoStat® technology observed in our previous first-in-man clinical trial. Data generated in the current study will be important for the advancement of the nanoemulsion adjuvant for NanoBio's flu vaccine as well as vaccines we are developing for RSV, UTI and several other diseases." Watch the full video to get more details from Dr Jakub ...
VID 00002-20100205-1530.3GP Driving the John Deere to get repaired for the big snowstorm of 2010 in Rapp
Applications of directed molecular evolution to DNA and conventional vaccines presents Applications of directed molecular evolution to DNA and conventional vaccines Dr. Robert Whalen of Altravax (Sunnyvale, CA) presents on directed molecular evolution to DNA and conventional vaccines in this webinar series. Because there is no clear understanding of what aspects of protein structure are important for immunogenicity, rational design approaches are of limited value in improving immunogens. Directed molecular evolution consists of creating a pool of sequence diversity and screening that diversity for variants that are improved in a given function. In this webinar, the MolecularBreeding™ directed molecular evolution technology will be discussed with examples of how it can be applied to improvement of vaccines.
What was the big news from the American College of Rheumatology meeting? Neovacs announced results of a Phase I/II clinical trial with polyclonal antibody IFNα-Kinoid in lupus patients at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago, IL. The trial results confirmed that IFNα-Kinoid active immunotherapy demonstrated good safety, immunogenicity and significant activity on lupus biomarkers. The trial results showed that all lupus patients who received the IFNα-Kinoid produced antibodies to IFNα and that administration of the IFNα-Kinoid, especially at the higher doses of 120mcg and 240mcg, had a statistically significant impact on the dysregulation of genes related to interferon α (the interferon signature) as well as those associated with lupus disease (the lupus signature). Trial results also showed a statistically significant relationship between the level of anti-IFNα antibody and the increase in complement C3, an established biomarker in lupus as well as the reduction of the IFNα gene signature and a fall in the levels of antibodies to dsDNA, another key marker for lupus disease activity. Neovacs Chief Executive Officer Guy-Charles Fanneau de La Horie French biotechnology company Neovacs (Alternext Paris : ALNEV) has developed a novel active immunotherapy vaccine-like platform for treatment of autoimmune and inflammatory diseases including lupus, Crohn's disease and rheumatoid arthritis called the Kinoid, that uses the body's own immune system to produce polyclonal antibodies to suppress disease-causing ...
Kymos video Kymos commercial video. Kymos is an ***ytical CRO of immunoassay, immunogenicity testing, bio***ysis and quality control of pharmaceuticals and biologicals.
Anti-drug antibodies Short depiction of Immunogenicity, an immune response raised by the body to a therapeutic drug that results in the development of anti-drug antibodies. Part of a series of animations and other module content developed for an iPad application.
ADVERSE IMMUNE REACTIONS (Part 3/3) Immunogenicity: Assessing the clinical relevance and risk minimization of antibodies to biopharmaceuticals Presenter: Daniel Kramer - EFPIA topic writer Moderator: Maria Teresa De Magistris
ADVERSE IMMUNE REACTIONS_Q&A (Part 2/2) Immunogenicity: Assessing the clinical relevance and risk minimization of antibodies to biopharmaceuticals Presenter: Daniel Kramer - EFPIA topic writer Moderator: Maria Teresa De Magistris
I like Immunogenicity - The Pharma Encyclopedia Picture Puzzle What has Tutanchamun in common with Immunogenicity? This time a really tricky picture puzzle! Have fun. Powered by , the Matchmaker for the Pharmaceutical Industry.
Vaccine development: Vaccine Enhancement Patch- Dr Larry Ellingsworth Subscribe: Hear Dr Larry Ellingsworth, CSO, Intercell USA deliver a presentation: Vaccine Enhancement Patch -- a simple and innovative way of improving injectable vaccines at the World Vaccine Washington Congress last April. • The Vaccine Enhancement Patch (VEP) can be added onto existing vaccines to significantly improve their immunogenicity • Add-on application does not require reformulation; GMP manufacturing process is in place • A novel adjuvant strategy for use with DNA vaccines • Clinical proof of principle demonstrated in multiple indications supported by a large safety database Visit our Website: Read our blog: Follow us on Twitter: @vaccinenation Join our Linkedin group:
New HIV therapeutic vaccine candidate Investigators from the AIDS and Infectious Diseases team of the Hospital Clínic/IDIBAPS- HIVACAT report in Science Translational Medicine the safety, tolerability, immunogenicity and virologic response results obtained with a new HIV therapeutic vaccine candidate. There is still a lot of work to do, but the new results are the best ones publishet in the scientific literature untill now. For further information:
News Update: Novavax (NASDAQ:NVAX) Climbs Early on Positive Influenza Vaccine Study Results 3/24/2010-Shares of Novavax (NASDAQ:NVAX) are trading 5.6% higher to $2.47 premarket Wednesday after the company announced what it called positive results from Stage A of its two-stage study evaluating the safety and effectiveness of a pandemic influenza vaccine. The data showed that safety and immunogenicity among the entire 1000-person study population were consistent with preliminary results previously disclosed from the first 500 volunteers of Stage A, in which the vaccine was found to be well-tolerated and immunogenic at all three dose levels tested.
Mock Up Vaccines (See More Info !) Initial Information About Mock-Up Vaccines Was Shared By YT User RadioTrunews ! Thanks! FROM Dr. Leonard Horowitz 9-6-9 RENSE DOT COM: Mock-up vaccines are made from live genetically-engineered viruses that spread like the flu after injection. So the threatening pandemic may include genetic parts, and whole new viruses, from these new laboratory produced pathogens. "Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus," the WHO wrote. "For all we know, deadly avian and Spanish flu viruses unearthed by vaccine companies is 'mocked-up' in these vaccines," Dr. Horowitz commented. "You literally need 'national security clearance' to get the full ingredients list." FROM MEDICAL NEWS TODAY WEBSITE 6 AUGUST 2009: Baxter International Inc. (NYSE: BAX) today announced that it completed production of its first commercial batches of CELVAPAN A/H1N1 pandemic vaccine in late July and is discussing plans for distribution with national health authorities, subject to obtaining appropriate authorizations. CELVAPAN, the brand name for the company's A/H1N1 pandemic influenza vaccine, is made using Baxter's proprietary Vero cell culture technology. Baxter plans to deliver initial quantities of CELVAPAN to national public health authorities that have pandemic agreements with the company. These health authorities placed orders for the vaccine following the World Health ...
Navigating the Regulatory Hierarchy of Concerns to Minimize Impact of Immunogenicity-Related Risks
iPS Cell Biology: CIRM Spotlight on Research Bottlenecks On June 23, 2011, Yang Xu spoke to the CIRM governing board about research bottlenecks in induced pluripotent (iPS) stem cell biology. iPS cells are created from a person's own tissue (eg skin) and yet have many characteristics of embryonic stem cells. It was assumed that iPS would not be rejected by a person's immune system when they are transplanted back into that same individual. However, Dr. Xu presented research results done in mice that indicate re-transplantation of iPS can lead to rejection by the immune system. Xu is a professor of biology at the University of California, San Diego and has a CIRM Early Translation grant.